Literature DB >> 10869368

Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist.

E Chu1, T C Chu, D E Potter.   

Abstract

The purpose of this study was to investigate mechanism(s) and site(s) of action involved in 7-hydroxy-2-dipropylaminotetralin (7-OH-DPAT)-induced ocular hypotension. As measured by pneumatonometry, the topical, unilateral application of 7-OH-DPAT (75 microg), a dopamine D(3)-preferring receptor agonist, decreased the intraocular pressure (IOP) bilaterally. The ocular hypotensive activity of 7-OH-DPAT was diminished in sympathetically denervated rabbits. Pretreatment with raclopride, a D(2)/D(3) receptor antagonist; UH232, a D(3) receptor antagonist; or U-99194A, a D(3) receptor antagonist antagonized 7-OH-DPAT-induced ocular hypotension. However, pretreatment with spiperone, a D(2) receptor antagonist, did not affect the 7-OH-DPAT-induced ocular hypotension. In addition, topically applied 7-OH-DPAT caused a reduction of aqueous humor flow rate. To examine sites of action, immunohistochemistry of D(3) dopamine receptors was performed. Dopamine D(3) receptors were found to be present on postganglionic sympathetic nerves in the ciliary body of normal rabbits but were virtually undetectable in the same tissue of sympathectomized rabbits. In summary, the IOP-lowering effect caused by 7-OH-DPAT was due, in part, to the suppression of aqueous humor flow. Immunohistochemical identification of D(3) receptors in the ciliary body, associated with the diminution of IOP-lowering effects by D(3) receptor agonist 7-OH-DPAT in sympathetically denervated rabbits provided evidence of neuronal site of action of 7-OH-DPAT. Suppression of 7-OH-DPAT-induced ocular hypotension by D(3) receptor antagonists (U-99194A and UH232) and sympathectomy, coupled with the immunohistochemical data, suggested that the primary site of D(3) receptor-mediated action of 7-OH-DPAT is located on postganglionic sympathetic nerve endings in the ciliary body of rabbit.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869368

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

Review 1.  Recent patents on ophthalmic nanoformulations and therapeutic implications.

Authors:  Ann-Marie Ako-Adounvo; Ramesh C Nagarwal; Lais Oliveira; Sai H S Boddu; Xiang S Wang; Surajit Dey; Pradeep K Karla
Journal:  Recent Pat Drug Deliv Formul       Date:  2014

2.  Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation.

Authors:  Chiara Bianca Maria Platania; Salvatore Salomone; Gian Marco Leggio; Filippo Drago; Claudio Bucolo
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

3.  Expression of Melatonin and Dopamine D3 Receptor Heteromers in Eye Ciliary Body Epithelial Cells and Negative Correlation with Ocular Hypertension.

Authors:  Irene Reyes-Resina; Hanan Awad Alkozi; Anna Del Ser-Badia; Juan Sánchez-Naves; Jaume Lillo; Jasmina Jiménez; Jesús Pintor; Gemma Navarro; Rafael Franco
Journal:  Cells       Date:  2020-01-08       Impact factor: 6.600

Review 4.  Role of dopaminergic receptors in glaucomatous disease modulation.

Authors:  Nicola Pescosolido; Francesco Parisi; Paola Russo; Giuseppe Buomprisco; Marcella Nebbioso
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.